US2940972A
(en)
|
1957-06-27 |
1960-06-14 |
Thomae Gmbh Dr K |
Tri-and tetra-substituted pteridine derivatives
|
GB1583753A
(en)
|
1976-07-14 |
1981-02-04 |
Science Union & Cie |
Piperidine derivatives processes for their preparation and pharmaceutical compositions containing them
|
US4666828A
(en)
|
1984-08-15 |
1987-05-19 |
The General Hospital Corporation |
Test for Huntington's disease
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
US4801531A
(en)
|
1985-04-17 |
1989-01-31 |
Biotechnology Research Partners, Ltd. |
Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
|
US5272057A
(en)
|
1988-10-14 |
1993-12-21 |
Georgetown University |
Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
|
US5192659A
(en)
|
1989-08-25 |
1993-03-09 |
Genetype Ag |
Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
|
GB9125001D0
(en)
|
1991-11-25 |
1992-01-22 |
Ici Plc |
Heterocyclic compounds
|
TW219935B
(pt)
|
1991-12-25 |
1994-02-01 |
Mitsubishi Chemicals Co Ltd |
|
EP0763537A3
(en)
|
1993-05-14 |
1997-10-22 |
Genentech Inc |
Non-peptides farnesyl transfer inhibitors
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
US6331555B1
(en)
|
1995-06-01 |
2001-12-18 |
University Of California |
Treatment of platelet derived growth factor related disorders such as cancers
|
US6218529B1
(en)
|
1995-07-31 |
2001-04-17 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
|
WO1998004689A1
(en)
|
1995-07-31 |
1998-02-05 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate disease
|
TW472045B
(en)
|
1996-09-25 |
2002-01-11 |
Astra Ab |
Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
|
AP1444A
(en)
|
1997-05-28 |
2005-07-18 |
Aventis Pharma Inc |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases.
|
US6235740B1
(en)
|
1997-08-25 |
2001-05-22 |
Bristol-Myers Squibb Co. |
Imidazoquinoxaline protein tyrosine kinase inhibitors
|
UA71555C2
(en)
|
1997-10-06 |
2004-12-15 |
Zentaris Gmbh |
Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
|
JP2002534512A
(ja)
|
1999-01-15 |
2002-10-15 |
ノボ ノルディスク アクティーゼルスカブ |
非ペプチドglp−1アゴニスト
|
JP4619545B2
(ja)
|
1999-03-17 |
2011-01-26 |
アストラゼネカ アクチボラグ |
アミド誘導体
|
CZ2002846A3
(cs)
|
1999-09-15 |
2003-02-12 |
Warner-Lambert Company |
Pteridinony, jako inhibitory kinasy
|
DE10013318A1
(de)
|
2000-03-17 |
2001-09-20 |
Merck Patent Gmbh |
Formulierung enthaltend Chinoxalinderivate
|
WO2002076985A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
US20030114448A1
(en)
|
2001-05-31 |
2003-06-19 |
Millennium Pharmaceuticals, Inc. |
Inhibitors of factor Xa
|
ES2295441T3
(es)
|
2001-12-18 |
2008-04-16 |
MERCK & CO., INC. |
Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato.
|
CA2471577C
(en)
|
2001-12-24 |
2011-08-02 |
Astrazeneca Ab |
Chemical compounds
|
JP2003213463A
(ja)
|
2002-01-17 |
2003-07-30 |
Sumitomo Chem Co Ltd |
金属腐食防止剤および洗浄液
|
AU2002249275A1
(en)
|
2002-03-08 |
2003-09-22 |
Warner-Lambert Company Llc |
Oxo azabicyclic compounds
|
CA2480800C
(en)
|
2002-04-08 |
2008-09-23 |
Mark T. Bilodeau |
Inhibitors of akt activity
|
US7074534B2
(en)
|
2002-07-10 |
2006-07-11 |
E. I. Du Pont De Nemours And Company |
Polymeric charge transport compositions and electronic devices made with such compositions
|
US7825132B2
(en)
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
CA2500727A1
(en)
|
2002-10-03 |
2004-04-15 |
Targegen, Inc. |
Vasculostatic agents and methods of use thereof
|
AR043059A1
(es)
|
2002-11-12 |
2005-07-13 |
Bayer Pharmaceuticals Corp |
Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos
|
US7098332B2
(en)
|
2002-12-20 |
2006-08-29 |
Hoffmann-La Roche Inc. |
5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
|
BRPI0406809A
(pt)
|
2003-01-17 |
2005-12-27 |
Warner Lambert Co |
Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
|
WO2004098494A2
(en)
|
2003-04-30 |
2004-11-18 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
EP1628666B1
(en)
|
2003-05-14 |
2015-09-23 |
NeuroGenetic Pharmaceuticals, Inc. |
Compouds and uses thereof in modulating amyloid beta
|
CA2524525C
(en)
|
2003-05-23 |
2012-01-03 |
Zentaris Gmbh |
Novel pyridopyrazines and use thereof as kinase modulators
|
DE10323345A1
(de)
|
2003-05-23 |
2004-12-16 |
Zentaris Gmbh |
Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
|
WO2005007099A2
(en)
|
2003-07-10 |
2005-01-27 |
Imclone Systems Incorporated |
Pkb inhibitors as anti-tumor agents
|
US7339065B2
(en)
|
2003-07-21 |
2008-03-04 |
Bethesda Pharmaceuticals, Inc. |
Design and synthesis of optimized ligands for PPAR
|
US7511145B2
(en)
|
2003-08-01 |
2009-03-31 |
Genelabs Technologies, Inc. |
Bicyclic heteroaryl derivatives
|
ATE369862T1
(de)
|
2003-10-17 |
2007-09-15 |
4 Aza Ip Nv |
Heterocyclus-substituierte pteridin-derivate und ihre verwendung in der therapie
|
AU2004288709B2
(en)
|
2003-11-07 |
2011-01-06 |
Novartis Vaccines And Diagnostics, Inc. |
Methods for synthesizing quinolinone compounds
|
WO2005054201A1
(en)
|
2003-11-20 |
2005-06-16 |
Janssen Pharmaceutica N.V. |
6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
|
KR100861515B1
(ko)
|
2003-11-24 |
2008-10-02 |
에프. 호프만-라 로슈 아게 |
피라졸릴 및 이미다졸릴 피리미딘
|
CA2548374C
(en)
|
2003-12-23 |
2014-05-27 |
Astex Therapeutics Limited |
Pyrazole derivatives as protein kinase modulators
|
US7098222B2
(en)
|
2004-05-12 |
2006-08-29 |
Abbott Laboratories |
Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
|
US7205316B2
(en)
|
2004-05-12 |
2007-04-17 |
Abbott Laboratories |
Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
|
KR20070048798A
(ko)
|
2004-08-31 |
2007-05-09 |
아스트라제네카 아베 |
퀴나졸리논 유도체 및 이것의 b-raf 억제제로서의 용도
|
JP2008516905A
(ja)
|
2004-10-14 |
2008-05-22 |
エフ.ホフマン−ラ ロシュ アーゲー |
Cdk1抗増殖活性を有する1,5−ナフチリジンアゾリジノン
|
KR20070063044A
(ko)
|
2004-10-15 |
2007-06-18 |
아스트라제네카 아베 |
B-raf 억제제로서의 퀴녹살린
|
US7795275B2
(en)
|
2004-12-24 |
2010-09-14 |
Uniquest Pty Limited |
Method of treatment or prophylaxis
|
EP1848704A4
(en)
|
2005-02-14 |
2011-05-11 |
Bionomics Ltd |
NEW TUBULIN POLYMERIZATION INHIBITORS
|
EP1853261B1
(de)
|
2005-03-03 |
2017-01-11 |
Universität des Saarlandes |
Selektive hemmstoffe humaner corticoidsynthasen
|
US20090156617A1
(en)
|
2005-05-12 |
2009-06-18 |
Northrup Alan B |
Tyrosine kinase inhibitors
|
BRPI0611521A2
(pt)
|
2005-05-18 |
2010-09-14 |
Wyeth Corp |
inibidores de 4,6-diamino-[1,7]naftiridina-3-carbonitrila de quìnase tpl2 e métodos de fabricação e uso dos mesmos
|
GB0513692D0
(en)
|
2005-07-04 |
2005-08-10 |
Karobio Ab |
Novel pharmaceutical compositions
|
NZ565749A
(en)
|
2005-08-26 |
2010-12-24 |
Serono Lab |
Pyrazine derivatives and use as PI3K inhibitors
|
WO2007054556A1
(de)
|
2005-11-11 |
2007-05-18 |
Æterna Zentaris Gmbh |
Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
|
EP1790342A1
(de)
|
2005-11-11 |
2007-05-30 |
Zentaris GmbH |
Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
|
US8217042B2
(en)
|
2005-11-11 |
2012-07-10 |
Zentaris Gmbh |
Pyridopyrazines and their use as modulators of kinases
|
MX2008008277A
(es)
|
2005-12-21 |
2009-03-04 |
Janssen Pharmaceutica Nv |
Triazolopiridazinas como moduladores de tirosina cinasa.
|
EP2024342A2
(en)
|
2006-05-01 |
2009-02-18 |
Pfizer Products Incorporated |
Substituted 2-amino-fused heterocyclic compounds
|
GB0609621D0
(en)
|
2006-05-16 |
2006-06-21 |
Astrazeneca Ab |
Novel co-crystal
|
US20100234347A1
(en)
|
2006-05-24 |
2010-09-16 |
Boehringer Ingelheim Internationl Gmbh |
Substituted Pteridines substituted with a Four-Membered Heterocycle
|
JO3235B1
(ar)
|
2006-05-26 |
2018-03-08 |
Astex Therapeutics Ltd |
مركبات بيررولوبيريميدين و استعمالاتها
|
US20100016293A1
(en)
|
2006-07-03 |
2010-01-21 |
Rogier Adriaan Smits |
Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use
|
JP2008127446A
(ja)
|
2006-11-20 |
2008-06-05 |
Canon Inc |
1,5−ナフチリジン化合物及び有機発光素子
|
AU2007334456A1
(en)
|
2006-12-13 |
2008-06-26 |
Merck Sharp & Dohme Corp. |
Methods of cancer treatment with IGF1R inhibitors
|
AU2007336811A1
(en)
|
2006-12-21 |
2008-07-03 |
Plexxikon, Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
AU2007336893A1
(en)
|
2006-12-22 |
2008-07-03 |
Novartis Ag |
Quinazolines for PDK1 inhibition
|
AR064491A1
(es)
|
2006-12-22 |
2009-04-08 |
Astex Therapeutics Ltd |
Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr.
|
KR20080062876A
(ko)
|
2006-12-29 |
2008-07-03 |
주식회사 대웅제약 |
신규한 항진균성 트리아졸 유도체
|
EP1990342A1
(en)
|
2007-05-10 |
2008-11-12 |
AEterna Zentaris GmbH |
Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
|
PE20090288A1
(es)
|
2007-05-10 |
2009-04-03 |
Smithkline Beecham Corp |
Derivados de quinoxalina como inhibidores de la pi3 quinasa
|
JP2010529031A
(ja)
|
2007-05-29 |
2010-08-26 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
Pi3キナーゼ阻害剤としてのナフチリジン誘導体
|
AR066879A1
(es)
|
2007-06-08 |
2009-09-16 |
Novartis Ag |
Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
|
CA2690226C
(en)
|
2007-06-20 |
2012-07-24 |
Mitsubishi Tanabe Pharma Corporation |
Novel malonic acid sulfonamide derivative and pharmaceutical use thereof
|
WO2008155378A1
(en)
|
2007-06-21 |
2008-12-24 |
Janssen Pharmaceutica Nv |
Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline
|
WO2009009016A1
(en)
|
2007-07-06 |
2009-01-15 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
JP5298128B2
(ja)
|
2007-08-08 |
2013-09-25 |
グラクソスミスクライン エルエルシー |
癌の治療用のIGF−1R阻害剤としての2−[(2−{フェニルアミノ}−1H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ]ベンズアミド誘導体
|
JP2010535804A
(ja)
|
2007-08-09 |
2010-11-25 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
Pi3キナーゼ阻害薬としてのキノキサリン誘導体
|
WO2009019518A1
(en)
|
2007-08-09 |
2009-02-12 |
Astrazeneca Ab |
Pyrimidine compounds having a fgfr inhibitory effect
|
US20090054304A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
US8309718B2
(en)
|
2007-11-16 |
2012-11-13 |
Incyte Corporation |
4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
|
EP2282739A2
(en)
|
2008-05-05 |
2011-02-16 |
Schering Corporation |
Sequential administration of chemotherapeutic agents for treatment of cancer
|
AU2009248774B2
(en)
|
2008-05-23 |
2012-05-31 |
Novartis Ag |
Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
|
WO2010059771A1
(en)
|
2008-11-20 |
2010-05-27 |
Osi Pharmaceuticals, Inc. |
Substituted pyrrolo[2,3-b]-pyridines and-pyrazines
|
CN102361863B
(zh)
|
2009-01-21 |
2014-12-03 |
巴斯利尔药物股份公司 |
新的二环抗生素
|
US20110288090A1
(en)
|
2009-02-02 |
2011-11-24 |
Armstrong Donna J |
Inhibitors of AKT Activity
|
TW201041888A
(en)
|
2009-05-06 |
2010-12-01 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
MX359575B
(es)
|
2009-06-12 |
2018-10-03 |
Abivax |
Compuestos utiles para tratar sida.
|
JP5696856B2
(ja)
|
2009-09-03 |
2015-04-08 |
バイオエナジェニックス |
Paskの阻害用複素環式化合物
|
JP5728683B2
(ja)
|
2009-09-04 |
2015-06-03 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH |
チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
|
US9095596B2
(en)
|
2009-10-15 |
2015-08-04 |
Southern Research Institute |
Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
|
US20110123545A1
(en)
|
2009-11-24 |
2011-05-26 |
Bristol-Myers Squibb Company |
Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
|
EP2332939A1
(en)
|
2009-11-26 |
2011-06-15 |
Æterna Zentaris GmbH |
Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
|
NZ718622A
(en)
|
2010-03-30 |
2018-03-23 |
Verseon Corp |
Multisubstituted aromatic compounds as inhibitors of thrombin
|
GB201007286D0
(en)
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
WO2011146591A1
(en)
|
2010-05-19 |
2011-11-24 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
WO2011149937A1
(en)
|
2010-05-24 |
2011-12-01 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
GB201020179D0
(en)
*
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
CN102532141A
(zh)
|
2010-12-08 |
2012-07-04 |
中国科学院上海药物研究所 |
[1,2,4]三唑并[4,3-b][1,2,4]三嗪类化合物、其制备方法和用途
|
US8987257B2
(en)
|
2011-01-31 |
2015-03-24 |
Novartis Ag |
Heterocyclic derivatives
|
US20140037642A1
(en)
|
2011-02-02 |
2014-02-06 |
Amgen Inc. |
Methods and compositions relating to inhibition of igf-1r
|
CN106619647A
(zh)
|
2011-02-23 |
2017-05-10 |
因特利凯有限责任公司 |
激酶抑制剂的组合及其用途
|
WO2012118492A1
(en)
|
2011-03-01 |
2012-09-07 |
Array Biopharma Inc. |
Heterocyclic sulfonamides as raf inhibitors
|
EP2702173A1
(en)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
NZ617987A
(en)
|
2011-05-10 |
2016-02-26 |
Gilead Sciences Inc |
Fused heterocyclic compounds as sodium channel modulators
|
JP6002223B2
(ja)
|
2011-08-26 |
2016-10-05 |
ニューファーマ, インコーポレイテッド |
特定の化学的実体、組成物、および方法
|
US9518029B2
(en)
|
2011-09-14 |
2016-12-13 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
WO2013043935A1
(en)
|
2011-09-21 |
2013-03-28 |
Neupharma, Inc. |
Certain chemical entites, compositions, and methods
|
WO2013052699A2
(en)
|
2011-10-04 |
2013-04-11 |
Gilead Calistoga Llc |
Novel quinoxaline inhibitors of pi3k
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
MX340452B
(es)
|
2011-10-28 |
2016-07-08 |
Novartis Ag |
Novedosos derivados de purina y su uso en el tratamiento de enfermedades.
|
GB201118656D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
GB201118675D0
(en)
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
WO2013133351A1
(ja)
|
2012-03-08 |
2013-09-12 |
アステラス製薬株式会社 |
新規fgfr3融合体
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
US20150203589A1
(en)
|
2012-07-24 |
2015-07-23 |
The Trustees Of Columbia University In The City Of New York |
Fusion proteins and methods thereof
|
CA2898326C
(en)
|
2013-01-18 |
2022-05-17 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
TW201536291A
(zh)
|
2013-08-02 |
2015-10-01 |
Cephalon Inc |
單獨使用AXL/cMET抑制劑或與其它藥劑組合使用以治療多種癌症之方法
|
US9221804B2
(en)
|
2013-10-15 |
2015-12-29 |
Janssen Pharmaceutica Nv |
Secondary alcohol quinolinyl modulators of RORγt
|
WO2015144804A1
(en)
|
2014-03-26 |
2015-10-01 |
Astex Therapeutics Ltd |
Combinations
|
JO3512B1
(ar)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
|
CA2943687C
(en)
|
2014-03-26 |
2024-02-13 |
Astex Therapeutics Ltd |
Combinations of an fgfr inhibitor and an igf1r inhibitor
|
JOP20200201A1
(ar)
|
2015-02-10 |
2017-06-16 |
Astex Therapeutics Ltd |
تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
|
EP3258966A4
(en)
|
2015-02-19 |
2018-07-25 |
Bioclin Therapeutics, Inc. |
Methods, compositions, and kits for treatment of cancer
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|